Loading...
Loading...
Feltl and Company reiterated its Buy rating on DaVita
DVA and raised its price target from $111 to $121.
Feltl and Company said, "Solid revenue metrics effectively inline with our expectations: Gross revenue increased 12% over prior year to $2,023 million. Non-acquired revenue increased 4.4%; we believe anything between 4%-5% growth is more than respectable given the mature dynamics of the industry. DVA acquired 10 centers and opened 21 centers in the U.S. and 2 centers outside the U.S. Through three quarters DVA has acquired 71 centers and opened 48 in the U.S. While acquiring facilities can ebb and flow we maintain smaller dialysis operators simply are finding the bundle
reimbursement environment more challenging, and we expect continued acquisition activity over the next one to two years."
DaVita closed at $111.02 on Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in